Skip to main content
SpringerLink
Log in

Regional Chemotherapy of Melanoma

  • Chapter
Regional Chemotherapy

Part of the book series: Current Clinical Oncology ((CCO))

  • 102 Accesses

Abstract

In 1999, an estimated 40,300 Americans will be diagnosed with cutaneous melanoma. Of these, approx 50% will have primaries that occur on the extremity (1). Although most patients present with disease that can be cured with surgery alone, approx 10–15% of patients with extremity melanoma will develop local recurrence, satellitosis, or intransit disease that is difficult to control or cure (2). Indeed, the most common pattern of recurrence in patients treated for localized melanoma is local-regional (3–6). Patients at highest risk for recurrent disease are those who present with deep primary melanoma or clinically positive regional nodal disease, or both.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Balch CM, Houghton AN, and Peters LJ. Cutaneous melanoma, In DeVita VT, Hellman S, Rosenberg SA, (eds), Cancer: Principles and Practice of Oncology, 4th ed. Lippincott, Philadelphia, 1993, 1612.

    Google Scholar 

  2. Fraker DL. Hyperthermic regional perfusion for melanoma of the limbs, In Balch CM, et al. (eds), Cutaneous Melanoma, 3rd ed. Quality Medical, St. Louis, (1998) pp. 281–300.

    Google Scholar 

  3. Reintgen DS, Cox C, Singluff CL Jr, and Seigler HR. Recurrent malignant melanoma: the identification of prognostic factors to predict survival, Ann. Plast. Surg., 28 (1992) 45–49.

    Article  PubMed  CAS  Google Scholar 

  4. Fusi S, Ariyan S, and Sternlicht A. Data on first recurrence after treatment for malignant melanoma in a large patient population, Plast. Reconstr. Surg., 91 (1993) 94–98.

    Article  PubMed  CAS  Google Scholar 

  5. Milton GW, Shaw HM, Farago GA, and McCarthy WH. Tumor thickness and the site and time of first recurrence in cutaneous malignant melanoma (stage I), Br. J. Surg., 67 (1980) 543–546.

    Article  PubMed  CAS  Google Scholar 

  6. McCarthy WH, Shaw HM, Thompson JF, and Milton GW. Time and frequency of recurrence of cutaneous stage I malignant melanoma with guidelines for follow-up study, Surg. Gynecol. Obstet., 166 (1988) 497–502.

    PubMed  CAS  Google Scholar 

  7. Cohen MH, Jessup JM, Felix EL, Weese JL, and Herberman RB. Intralesional treatment of recurrent metastatic cutaneous malignant melanoma: a randomized prospective study of intralesional bacillus Calmette-Guérin versus intralesional dinitrochlorobenzene, Cancer, 41 (1978) 2456–2463.

    Article  PubMed  CAS  Google Scholar 

  8. Bauer R, Kopald K, Lee J, et al. Long term results of intralesional BCG for locally advanced recurrent melanoma, Proc. Am. Soc. Clin. Oncol., 9 (1990) 276.

    Google Scholar 

  9. von Wussow P, Block B, Hartmann F, and Deicher H. Intralesional interferon-alpha in advanced malignant melanoma, Cancer, 61 (1988) 1071–1974.

    Article  Google Scholar 

  10. Si Z, Hersey P, and Coates AS. Clinical responses and lymphoid infiltrates in metastatic melanoma following treatment with intralesional GM-CSF, Melanoma Res., 6 (1966) 247–255.

    Article  Google Scholar 

  11. Strobbe LJ, Nieweg 0E, and Kroon BB. Carbon dioxide laser for cutaneous melanoma metastases: indications and limitations, Eur. J. Surg. Oncol., 23 (1997) 435–438.

    Article  PubMed  CAS  Google Scholar 

  12. Buzaid AC, Bedikian A, and Houghton AN. Systemic chemotherapy and biochemotherapy, In Balch CM, et al., (eds), Cutaneous Melanoma, 3rd ed. Quality Medical, St. Louis, (1998) pp. 405–418.

    Google Scholar 

  13. Jaques DP, Coit DG, and Brennan MF. Major amputation for advanced malignant melanoma, Surg. Gynecol. Obset., 196 (1989) 1–6.

    Google Scholar 

  14. Turnbull A, Shah J, and Fortner J. Recurrent melanoma of an extremity treated by major amputation, Arch Surg, 106 (1973) 496–498.

    Article  PubMed  CAS  Google Scholar 

  15. Kourtesis GJ, McCarthy WH, and Milton GW. Major amputations for melanoma, Aust. NZ J. Surg., 53 (1983) 241–244.

    Article  CAS  Google Scholar 

  16. Stehlin JS Jr, Giovanella BC, De Ipolyi PD, Muenz LR, and Anderson RF. Results of hyperthermic perfusion for melanoma of the extremities, Surg. Gynecol. Obstet., 140 (1975) 339–348.

    PubMed  CAS  Google Scholar 

  17. Hartley JW and Fletcher WS. Improved survival of patients with stage II melanoma of the extremity using hyperthermic isolation perfusion with 1-phenylalanine mustard, J. Surg. Oncol.,36 (1987) 170–174.

    Article  PubMed  CAS  Google Scholar 

  18. Di Filippo F, Calabro A, Giannarelli D, et al. Prognostic variables in recurrent limb melanoma treated with hyperthermic antiblastic perfusion, Cancer, 63 (1989) 2551–2561.

    Article  PubMed  Google Scholar 

  19. Klaase JM, Kroon BBR, van Geel AN, et al. Limb recurrence-free interval and survival in patients with recurrent melanoma of the extremities treated with normothermic isolated perfusion, J. Am. Coll. Surg., 178 (1994) 564–572.

    PubMed  CAS  Google Scholar 

  20. Krementz ET, Carter RD, Sutherland CM, Muchmore JH, Ryan RF, and Creech O. Regional chemotherapy for melanoma. A 35-year experience, Ann. Surg., 220 (1994) 520–535.

    Article  PubMed  CAS  Google Scholar 

  21. Bryant PJ, Balderson GA, Mead P, and Egerton WS. Hyperthermic isolated limb perfusion for malignant melanoma: response and survival, World J. Surg., 19 (1995) 363–368.

    Article  PubMed  CAS  Google Scholar 

  22. Omlor G, Gross G, Ecker KW, Burger I, and Feifel G. Optimization of isolated hyperthermic limb perfusion, World J. Surg., 16 (1992) 1117–1119.

    Article  PubMed  CAS  Google Scholar 

  23. Cavaliere R, Ciocatto EC, Giovanella BC, et al. Selective heat sensitivity of cancer cells: biochemical and clinical studies, Cancer, 20 (1967) 1351–1381.

    Article  PubMed  CAS  Google Scholar 

  24. Creech O, Krementz ET, Ryan RF, and Winblad JN. Chemotherapy of cancer: regional perfusion utilizing an extracorporeal circuit, Ann. Surg., 148 (1958) 616–632.

    Article  PubMed  Google Scholar 

  25. Eggermont AMM. Treatment of melanoma in-transit metastases confined to the limb, Cancer Surveys, 26 (1996) 335–349.

    PubMed  CAS  Google Scholar 

  26. Stehlin JS Jr, Giovanella BC, de Ipolyi PD, and Anderson RF. Eleven years’ experience with hyperthermie perfusion for melanoma of the extremities, World J. Surg., 3 (1979) 305–307.

    Article  PubMed  Google Scholar 

  27. Vaglini M, Ammatuna M, Nava M, et al. Regional perfusion at high temperature in the treatment of stage IIIA-IIIAB melanoma patients, Tumori, 69 (1983) 585–588.

    PubMed  CAS  Google Scholar 

  28. Klaase JM, Kroon BBR, Eggermont AMM, et al. Retrospective comparative study evaluating the results of mild hyperthermic versus controlled normothermic perfusion for recurrent melanoma of the extremities, Eur. J. Cancer, 31A (1995) 58–63.

    Article  Google Scholar 

  29. Kroon BBR, van Geel AN, Benckhuijsen C, and Wieberdink J Normothermic isolation perfusion with melphalan for advanced melanoma of the limbs, Anticancer Res., 7 (1987) 441–442.

    PubMed  CAS  Google Scholar 

  30. Kroon BB, Klaase JM, van Geel BN, Eggermont AM, Franklin HR, and van Dongen JA. Results of a double perfusion schedule with melphalan in patients with melanoma of the lower limb, Eur. J. Cancer, 29A (1993) 325–328.

    Article  Google Scholar 

  31. Storm FK and Morton DL. Value of hyperthermic limb perfusion in advanced recurrent melanoma of the lower extremity, Am. J. Surg., 150 (1985) 32–35.

    Article  PubMed  CAS  Google Scholar 

  32. Bulman AS and Jamieson CW. Isolated limb perfusion with melphalan in the treatment of malignant melanoma, Br. J. Surg., 67 (1980) 660–662.

    Article  PubMed  CAS  Google Scholar 

  33. Skene AI, Bulman AS, Williams TR, Meirion Thomas J, and Westbury G. Hyperthermic isolated perfusion with melphalan in the treatment of advanced malignant melanoma of the lower limb, Br. J. Surg., 77 (1990) 765–767.

    Article  PubMed  CAS  Google Scholar 

  34. Minor DR, Allen RE, Alberts D, Peng Y-M, Tardelli G, and Hutchinson J. Clinical and pharmacokinetic study of isolated limb perfusion with heat and melphalan for melanoma, Cancer, 55 (1985) 2638–2644.

    Article  PubMed  CAS  Google Scholar 

  35. Lienard D, Lejeune FJ, and Ewalenko P. In transit metastases of malignant melanoma treated by high dose rTNF alpha in combination with interferon gamma and melphalan in isolation perfusion, World J. Surg., 16 (1992) 234–240.

    Article  PubMed  CAS  Google Scholar 

  36. Fraker DL, Alexander HR, Andrich M, and Rosenberg SA. Treatment of patients with melanoma of the extremity using hyperthermic isolated limb perfusion with melphalan, tumor necrosis factor, and interferon gamma: results of a tumor necrosis factor dose-escalation study, J. Clin. Oncol., 14 (1996) 479–489.

    PubMed  CAS  Google Scholar 

  37. Thompson JF, Hunt JA, Shannon KF, Colman MH, and Kam PCA. Frequency and duration of complete remission after therapeutic isolated limb perfusion for melanoma, Melanoma Res., 7 (Suppl 1) (1997) S33.

    Article  Google Scholar 

  38. Luck JM. Action of p[Di(2-chlorethyl)]-amino-L-phenylalanine on Harding-Passey mouse melanoma, Science, 123 (1956) 984–983.

    Article  PubMed  CAS  Google Scholar 

  39. Byrne DS, McKay AJ, Blackie R, and MacKie RM. Comparison of dosimetric methods in isolated limb perfusion with melphalan for malignant melanoma of the lower extremity, Eur. J. Cancer, 32A (1996) 2082–2087.

    Article  Google Scholar 

  40. Klaase JM, Kroon BBR, van Geel AN, Eggermont AMM, Franklin HR, and van Dongen JA. Retrospective comparative study evaluating the results of a single-perfusion versus double-perfusion schedule with melphalan in patients with recurrent melanoma of the lower limb, Cancer, 71 (1993) 2990–2994.

    Article  PubMed  CAS  Google Scholar 

  41. Fletcher WS, Pommier R, and Small K. Results of cisplatin hyperthermic isolation perfusion for stage IIIA and IIIAB extremity melanoma, Melanoma Res., 4 (1994) 17–19.

    PubMed  Google Scholar 

  42. Coit DG, Bajoran DF, and Menendez-Botet C. Phase I trial of hyperthermic isolation limb perfusion (HILP) using cisplatin (CDDP) for metastatic melanoma, Proc. Am. Soc. Clin. Oncol., 10 (1991) 294.

    Google Scholar 

  43. Hoekstra HJ, Schraffordt Koops HS, de Vries LG, van Weerden TW, and Oldhoff J. Toxicity of hyperthermic isolated limb perfusion with cisplatin for recurrent melanoma of the lower extremity after previous perfusion treatment, Cancer, 72 (1993) 1224–1229.

    Article  PubMed  CAS  Google Scholar 

  44. Thompson JF and Gianoutsos MP. Isolated limb perfusion for melanoma: effectiveness and toxicity of cisplatin compared with that of melphalan and other drugs, World J. Surg., 16 (1992) 227–233.

    Article  PubMed  CAS  Google Scholar 

  45. Santinami M, Belli F, Cascinelli N, et al. Seven years experience with hyperthermic perfusions in extracorporeal circulation for melanoma of the extremities, J. Surg. Oncol., 42 (1989) 201–208.

    Article  PubMed  CAS  Google Scholar 

  46. Anderson CM, Buzaid AC, and Legha SS. Systemic treatments for advanced cutaneous melanoma, Oncology 9 (1995) 1149–1158.

    PubMed  CAS  Google Scholar 

  47. Vaglini M, Belli F, Marolda R, Prada A, Santinami M, and Cascinelli N. Hyperthermic antiblastic perfusion with DTIC in stage IIIA-IIIAB melanoma of the extremities, Eur. J. Surg. Oncol., 13 (1987) 127–129.

    PubMed  CAS  Google Scholar 

  48. Aigner K, Hild P, Henneking K, Paul E, and Hundeiker M. Regional perfusion with cis-platinum and dacarbzine, Recent Res. Cancer Res., 86 (1983) 239–245.

    Article  CAS  Google Scholar 

  49. Didolkar MS, Viens ML, Suter CM, and Buda B. Phase II study on isolation perfusion with DTIC (imidazole carboxamide) in stage IIIA-IIIAB melanoma of the extremity, Proc. Am. Soc. Clin. Oncol., 9 (1990) 276.

    Google Scholar 

  50. Martijn H, Oldhoff J, and Koops HS. Hyperthermic regional perfusion with melphalan and a combination of melphalan and actinomycin D in the treatment of locally metastasized malignant melanomas of the extremities, J. Surg. Oncol., 20 (1982) 9–13.

    Article  PubMed  CAS  Google Scholar 

  51. Lejeune FJ. High dose recombinant tumour necrosis factor (rTNFa) administered by isolation perfusion for advanced tumours of the limbs: a model for biochemotherapy of cancer, Eur. J. Cancer, 31A (1995) 1009–1016.

    Article  Google Scholar 

  52. Lejeune F, Lienard D, Schraffordt Koops H, Kroon B, and Eggermont A. Treatment of in-transit melanoma metastases with tumour necrosis factor (TNF-a) and chemotherapy administered in isolated limb perfusion (ILP), Melanoma Res., 7 (1997) S48.

    Article  Google Scholar 

  53. Old LJ. Tumor necrosis factor (TNF), Science, 230 (1985) 630–632.

    Article  PubMed  CAS  Google Scholar 

  54. Alexander RB and Rosenberg SA. Tumor necrosis factor: clinical implications, In DeVita VT, Hellman S, and Rosenberg SA, (eds), Biologic Therapy of Cancer, Lippincott, Philadelphia, 1991, pp. 378–392.

    Google Scholar 

  55. Posner M, Lienard D, Lejeune F, Rosenfelder D, and Kirkwood J. Hyperthermic isolated limb perfusion (HILP) with tumor necrosis factor (TNF) alone for metastatic in transit melanoma, Proc. Am. Soc. Clin. Oncol., 13 (1994) 396.

    Google Scholar 

  56. Lienard D, Ewalenko P, Delmotte JJ, Renard N, and Lejeune FJ. High doses recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma, J. Clin. Oncol., 10 (1992) 52–60.

    PubMed  CAS  Google Scholar 

  57. Niitsu Y, Watanabe N, Umeno H, et al. Synergistic effects of recombinant human tumor necrosis factor and hyperthermia on in vitro cytotoxicity and artificial metastasis, Cancer Res., 48 (1988) 654–657.

    PubMed  CAS  Google Scholar 

  58. Watanabe N, Niitsu Y, Umeno H, et al. Synergistic cytotoxic and antitumor effects of recombinant human tumor necrosis factor and hyperthermia, Cancer Res., 48 (1988) 650–653.

    PubMed  CAS  Google Scholar 

  59. Balkwill F, Lee A, Aklom G, et al. Human tumor xenografts treated with recombinant human tumor necrosis factor alone or in combination with interferons, Cancer Res., 46 (1986) 3990–3993.

    PubMed  CAS  Google Scholar 

  60. Fiers W, Brouckaert P, and Guisez Y. Recombinant interferon gamma and its synergism with tumor necrosis factor in the human and mouse systems, In Schellekens H, Stewart WE, (eds), Biology of the Interferon System, Elsevier, Amsterdam, (1986) 241–248.

    Google Scholar 

  61. Gerain J, Lienard D, Ewalenko P, and Lejeune FJ. High serum levels of the TNF-alpha after its administration for isolation perfusion of the limb, Cytokine, 4 (1992) 585–591.

    Article  PubMed  CAS  Google Scholar 

  62. Eggimann P, Chiolero R, Chassot PG, Lienard D, Gerain J, and Lejeune F. Systemic and hemodynamic effects of recombinant tumor necrosis factor alpha in isolation perfusion of the limbs, Chest, 107 (1995) 1074–1082.

    Article  PubMed  CAS  Google Scholar 

  63. Bone RC, Balk RA, Cerra FB, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis, Chest, 101 (1992) 1644–1655.

    Article  PubMed  CAS  Google Scholar 

  64. Bartlett DL, Ma G, Alexander HR, Libutti SK, and Fraker DL. Isolated limb reperfusion with tumor necrosis factor and melphalan in patients with extremity melanoma after failure of isolated limb perfusion with chemotherapeutics, Cancer, 80 (1997) 2084–2090.

    Article  PubMed  CAS  Google Scholar 

  65. Fraker DL. What is the best regional therapy? Melanoma Res., 7 (1997) S42.

    Article  Google Scholar 

  66. McBride CM, Sugarbaker EV, and Hickey RC. Prophylactic isolation-perfusion as the primary therapy for invasive malignant melanoma of the limbs, Ann. Surg., 182 (1975) 316–324.

    Article  PubMed  CAS  Google Scholar 

  67. Edwards MJ, Soong SJ, Boddie AW, Balch CM, and McBride CM. Isolated limb perfusion for localized melanoma of the extremity, Arch. Surg., 125 (1990) 317–321.

    Article  PubMed  CAS  Google Scholar 

  68. Franklin HR, Koops HS, Oldhoff J, et al. To perfuse or not to perfuse? A retrospective comparative study to evaluate the effect of adjuvant isolated regional perfusion in patients with stage I extremity melanoma with a thickness of 1.5 mm or greater, J. Clin. Oncol., 6 (1988) 701.

    PubMed  CAS  Google Scholar 

  69. Ghussen F, Kruger I, Groth W, and Stutzer H. Role of regional hyperthermic cytostatic perfusion in the treatment of extremity melanoma, Cancer, 61 (1988) 654–659.

    Article  PubMed  CAS  Google Scholar 

  70. Fenn NJ, Horgan K, Johnson RC, Hughes LE, and Manse’ RE. Randomized controlled trial of prophylactic isolated cytotoxic perfusion for poor-prognosis primary melanoma of the lower limb, Eur. J. Surg. Oncol., 23 (1997) 6–9.

    Article  PubMed  CAS  Google Scholar 

  71. Schraffordt Koops H, Vaglini M, Kroon BBR, et al. Value of prophylactic isolated limb perfusion (ILP) for stage I high risk malignant melanoma: a randomized phase III trial, Melanoma Res., 7 (Suppl 1) (1997) S34.

    Article  Google Scholar 

  72. Hafstrom L, Rudenstam CM, Blomquist E, et al. Regional hyperthermic perfusion with melphalan after surgery for recurrent malignant melanoma of the extremities, J. Clin. Oncol., 9 (1991) 2091–2094.

    PubMed  CAS  Google Scholar 

  73. Gohl J, Meyer TH, and Hohenberger W. Hyperthermic isolated limb perfusion (HILP): a therapeutic concept in locoregional metastasized malignant melanoma. Experiences over 20 years, Melanoma Res., 7 (Suppl 1) (1997) 5101.

    Google Scholar 

  74. Krementz ET and Ryan RF. Chemotherapy of melanoma of the extremities by perfusion: fourteen years of clinical experience, Ann. Surg., 175 (1972) 900–917.

    Article  PubMed  CAS  Google Scholar 

  75. Rosin RD and Westbury G. Isolated limb perfusion for malignant melanoma, Practitioner, 224 (1980) 1031–1036.

    PubMed  CAS  Google Scholar 

  76. Taber SW and Polk HC. Mortality, major amputation rates, and leukopenia after isolated limb perfusion with phenylalanine mustard for the treatment of melanoma, Ann. Surg. Oncol., 4 (1997) 440–445.

    Article  PubMed  CAS  Google Scholar 

  77. Vrouenraets BC, Klaase JM, Kroon BBR, van Geel BN, Eggermont AMM, and Franklin HR. Longterm morbidity after regional isolated perfusion with melphalan for melanoma of the limbs, Arch. Surg., 130 (1995) 43–47.

    Article  PubMed  CAS  Google Scholar 

  78. Schraffordt Koops H. Prevention of neural and muscular lesions during hyperthermic regional perfusion, Surg. Gynecol. Obstet., 135 (1972) 401–403.

    PubMed  CAS  Google Scholar 

  79. Olieman AF, Schraffordt Koops H, Geertzen JH, Kingma H, Hoekstra HJ, and Oldhoff J. Functional morbidity of hyperthermic isolated regional perfusion of the extremities, Ann. Surg. Oncol., 1 (1994) 382–388.

    Article  PubMed  CAS  Google Scholar 

  80. Vrouenraets BC, in’t Veld GJ, Nieweg 0E, van Slooten GW, van Dongen JA, and Kroon BBR. Longterm functional morbidity after mild hyperthermic isolated limb perfusion (ILP) with melphalan, Melanoma Res., 7 (Suppl 1) (1997) S122.

    Article  Google Scholar 

  81. van Geel AN, van Wijk J, and Wieberdink J. Functional morbidity after regional isolated perfusion of the limb for melanoma, Cancer,63 (1989) 1092–1096.

    Article  PubMed  Google Scholar 

  82. Harman CR, Thompson JF, Hunt JA, Waugh RC, and Kam PC. Isolated limb infusion with cytotoxic agents for recurrent limb melanoma: results of 120 procedures, Melanoma Res., 7 (Suppl 1) (1997) S111.

    Article  Google Scholar 

  83. Thompson JF, Kam PCA, Waugh RC, and Hannan CR. Isolated limb infusion with cytotoxic agents: a simple alternative to isolated limb perfusion, Sem. Surg. Oncol., 14 (1998) 238–247.

    Article  CAS  Google Scholar 

Download references

Authors
  1. Mary S. Brady
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Daniel G. Coit
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. The Cleveland Clinic Taussig Cancer Center, Department of Hematology/Medical Oncology, The Cleveland Clinic Foundation, Cleveland, OH, USA

    Maurie Markman MD (Director, Chairman) (Director, Chairman)

Rights and permissions

Reprints and permissions

Copyright information

© 2000 Springer Science+Business Media New York

About this chapter

Cite this chapter

Brady, M.S., Coit, D.G. (2000). Regional Chemotherapy of Melanoma. In: Markman, M. (eds) Regional Chemotherapy. Current Clinical Oncology. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-219-7_4

Download citation

  • DOI: https://doi.org/10.1007/978-1-59259-219-7_4

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-4684-9697-0

  • Online ISBN: 978-1-59259-219-7

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation